Abstract
Previous work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.
Original language | English |
---|---|
Pages (from-to) | 168-171 |
Number of pages | 4 |
Journal | Australian and New Zealand Journal of Obstetrics and Gynaecology |
Volume | 62 |
Issue number | 1 |
DOIs | |
Publication status | Published or Issued - Feb 2022 |
Keywords
- cerebral palsy
- cost-benefit analysis
- magnesium sulphate
- quality improvement
ASJC Scopus subject areas
- Obstetrics and Gynaecology